Form 4: Amicus Therapeutics CEO Bradley Campbell Reports Stock Transactions

Amicus Therapeutics CEO Bradley Campbell reported multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Summary

• Amicus Therapeutics CEO Bradley Campbell reported several transactions involving the company's stock.
• On January 2, 2025, 20,647 shares were disposed of at a price of $9.31 per share.
• On January 3, 2025, 266,528 shares were acquired in the form of Restricted Stock Units (RSUs) at no cost.
• Also on January 3, 2025, 41,474 shares were disposed of at a price of $9.41 per share.
• On January 4, 2025, 7,368 shares were disposed of at a price of $9.41 per share.
• On January 3, 2025, 482,908 stock options were acquired with an exercise price of $9.41 per share.
• The RSUs will vest in four equal annual installments starting January 3, 2026.
• The stock options vest over a four-year period, with 25% vesting one year after the grant date and the remaining 75% vesting monthly thereafter.

Sentiment

Score: 6

Explanation: The document reflects standard insider transactions. While there are disposals, the acquisition of RSUs and options is generally positive. The sentiment is neutral to slightly positive.

Positives

• The acquisition of 266,528 RSUs by the CEO indicates a long-term commitment to the company's success.
• The grant of 482,908 stock options aligns the CEO's interests with those of shareholders.

Negatives

• The disposal of 20,647 shares on January 2, 2025, at $9.31 per share could be seen as a slight negative.
• The disposal of 41,474 shares on January 3, 2025, and 7,368 shares on January 4, 2025, at $9.41 per share may raise some concerns.

Risks

• The vesting schedule of the RSUs and stock options could influence the CEO's short-term decisions.
• The disposal of shares by the CEO, even if for tax purposes, could be interpreted negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in the biotechnology and pharmaceutical industries.
• Vesting schedules of four years for options and annual installments for RSUs are typical in the industry.
• Similar filings are regularly made by executives at companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the acquisition of RSUs and stock options as a positive sign of the CEO's commitment.
• The disposal of shares may cause some short-term concern among shareholders.

Key Dates

Keywords

Amicus Therapeutics, stock transactions, insider trading, restricted stock units, stock options, CEO, Bradley Campbell, vesting